UroGen secures US patent protecting ZUSDURI to July 2044

UroGen Pharma has received a Notice of Allowance from the US Patent and Trademark Office for a patent application covering methods of treating patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) without surgical tumour resection. The allowed patent, once formally issued, will carry an expiration date in July 2044, extending intellectual property protection for the company's commercialised product ZUSDURI and its investigational successor UGN-103.

The patent claims are supported by clinical data from the ENVISION and ATLAS trials of ZUSDURI, which is a mitomycin formulation delivered intravesically using UroGen's proprietary RTGel reverse-thermal hydrogel technology. RTGel transitions from liquid to gel at body temperature, enabling sustained local drug exposure within the bladder without the need for a transurethral resection of a bladder tumour (TURBT).

The Products and Their IP Position

ZUSDURI received FDA approval as the first and only therapy indicated for adults with recurrent LG-IR-NMIBC, positioning UroGen as the category-defining company in a niche but commercially meaningful segment of uro-oncology. The newly allowed patent adds a method-of-treatment layer to UroGen's existing IP estate.

UGN-103, a next-generation programme developed under a licensing and supply agreement signed with Germany's medac group in January 2024, is designed to build on ZUSDURI's clinical profile while incorporating manufacturing simplifications and a more streamlined reconstitution process. UroGen already holds separate US patents covering the combination of RTGel with medac's lyophilised mitomycin formulation, with those rights expected to run to December 2041. The new allowance, if issued, would extend the ceiling of IP protection by a further three years.

Liz Barrett, President and Chief Executive Officer of UroGen, said the allowance "underscores the innovation behind our proprietary RTGel technology" and reflects the company's ability to deliver mitomycin as a primary, non-surgical treatment option, adding that the approach "helps patients achieve highly durable recurrence-free intervals while reducing the burden of repeat surgical interventions."

Market Context and Competitive Landscape

Non-muscle-invasive bladder cancer is a high-recurrence disease, with standard-of-care management historically centred on repeated TURBT procedures and intravesical BCG immunotherapy. BCG has faced persistent global supply shortages, creating space for alternative intravesical regimens. UroGen's RTGel platform addresses a specific subset of this patient population and, as the only FDA-approved non-surgical option for LG-IR-NMIBC, has limited direct competition in its approved indication today.

Longer-term, the uro-oncology landscape is growing more crowded. Several companies are developing novel intravesical agents and drug-device combinations for bladder cancer, and the FDA has signalled appetite for innovative local delivery approaches as part of its oncology programme priorities. Sustained IP coverage to 2044 is commercially significant: it gives UroGen a meaningful runway to build market share with ZUSDURI and, if approved, to launch UGN-103 with confidence that biosimilar or generic erosion remains distant.

For investors, the key near-term catalyst remains regulatory progress on UGN-103, where the UTOPIA trial dataset will determine whether a supplemental or new approval can be secured. The patent allowance itself is a defensive milestone rather than a revenue event, but it materially de-risks the long-term return profile of the franchise.